First In Vivo Human Genome Editing to Be Tested in New Clinical Trial

Sangamo Therapeutics will use zinc finger nucleases to introduce the gene for a missing clotting factor into the livers of men with hemophilia B.

By | May 18, 2017

MEDICALGRAPHICS.DEResearchers have edited the human genome before, but always in cells outside the body. Now, biotech company Sangamo Therapeutics is recruiting participants for clinical trials in which patients with hemophilia B, Hurler syndrome, or Hunter syndrome will have the gene coding for one of the enzymes that is non-functional in them stitched into their genomes at double-stranded DNA breaks caused by zinc finger nucleases.

“This is the first time someone could have a new gene put into their liver,” Sangamo President and CEO Sandy Macrae told The Scientist. “It’s a privilege and a responsibility to do” these trials.

One of the diseases Sangamo will focus on is hemophilia B, which is a severe bleeding disorder caused by a defective or absent gene called F9. The gene’s protein product, coagulation factor IX, is an enzyme essential for blood clotting.

Two other clinical trials will focus on Hurler and Hunter syndromes. People with these disorders lack a functional copy of two different genes that code for enzymes necessary for breaking down complex polysaccharides involved in development, angiogenesis, and more. Without these enzymes, specific types of polysaccharides called glycosaminoglycans build up in cells, which can cause neurologic issues and cardiovascular disease, among other complications.

In all three trials, the zinc finger nucleases cut a target spot in the gene for albumin in hepatocytes, and the functional copy of the relevant gene is incorporated by homologous recombination.

The initial phase of one trial involves three pairs of men with severe hemophilia B, who will each receive a low, medium, or high intravenous dose of a drug called SB-FIX, composed of three adeno-associated viruses: two contain the genes for the zinc finger nucleases and the third has the functional F9 gene.

Macrae said the investigators expect that F9 DNA will be incorporated into the target site in the albumin gene in a minority of hepatocytes, but because albumin is so highly expressed in the liver, the patients’ levels of factor IX enzymes could still increase. Once the Sangamo team assesses the drug’s safety and determines its optimal dose, three more men with hemophilia B will enter the trial as part of that dosage group.

Hemophilia B “is a logical first disease to target because the disease physiology is pretty straightforward,” said Andrew Davidoff, a pediatric surgeon at St. Jude Children’s Research Hospital in Memphis, Tennessee. “If you just replace the missing or defective clotting factor you will essentially cure the patients,” he explained.

Davidoff is not involved in Sangamo’s upcoming trial, but he has led clinical trials for men with hemophilia B, in which adeno-associated viruses deliver a functional copy of F9 to the liver. The gene cassette in Davidoff’s trials is not incorporated into the patients’ genomes, instead existing in liver cells as extra-genomic DNA called episomes. “By not integrating, if the target cell divides you may lose that material,” Davidoff explained.

But even without genomic integration of F9, the men that received the treatment in Davidoff’s trials still had increases in the clotting factor that led to clinical improvements. The earliest participants have shown consistent levels of circulating factor IX for more than seven years. “It’s been a little surprising that things have been so stable,” Davidoff said. “Part of the answer is that the liver cells rarely divide in the absence of trauma or surgery.”

Macrae said that one advantage of Sangamo’s strategy in the current trials is that it is “a lifelong solution.” Once the zinc finger nucleases facilitate integration of the functional copy of the gene into the genomes of participants’ liver cells, F9 should be stably expressed.

Paula Cannon, a gene therapy researcher at the University of Southern California’s Keck School of Medicine in Los Angeles, described the albumin gene as a “safe harbor site”—a genomic location that has been determined experimentally to be a good place for genes to be inserted and expressed long-term. Cannon is not involved in the current trials, but she worked with Sangamo previously to use zinc finger nucleases to edit a gene in human cells to make the cells’ progeny resistant to HIV infection.

Both zinc finger nucleases and the CRISPR/Cas9 system are capable of cutting DNA in a site-specific manner, Cannon told The Scientist, but she added that there are advantages for zinc finger nucleases in developing clinical therapies. For instance, CRISPR/cas9 has some limitations, namely, that the guide RNA that binds to the target sequence must attach to an anchor sequence, typically two Gs. Thus, CRISPR/Cas9 “doesn’t give you quite the degree of specificity,” she said.

“Zinc finger nucleases are a little more cumbersome to develop,” Cannon added, but Sangamo’s system “gives you very specific and highly effective zinc finger nucleases. They can target ZFNs to cut at any particular base.”

Another advantage of zinc finger nucleases that Cannon highlighted is their history and approval as investigational new drugs by the US Food and Drug Administration. Zinc finger nucleases have been successfully used to knock out a gene that is involved with HIV entry in human T-cells’ genomes, and when injected in humans, those cells did not elicit an immune response.

One more benefit of zinc finger nucleases is that they are smaller than Cas9, the enzyme required for the CRISPR/Cas9 system. “For situations where you’re editing cells outside of the body, that doesn’t matter,” Cannon said. “But if you’re thinking about treating tissues in vivo, as this current trial will be, then you’re looking at a class of vectors called adeno-associated virus vectors. And it’s really hard to squash Cas9 into them because it is just too big.”

Yet, some obstacles to in vivo genome editing are universal. “Whether you’re using zinc finger nucleases or similar proteins called TALENs or the CRISPR system, you have a delivery problem, meaning, how do you actually get your product of interest into specific cells and not others,” said Robert Doms, a pathologist at the University of Pennsylvania School of Medicine who is not involved in the current clinical trials. “That’s been a challenge for gene therapy no matter what you’re trying to do.”

For Sangamo’s current trials, getting any of the drugs to the liver is fairly straightforward, as the adeno-associated virus readily enters hepatocytes from the blood. Macrae explained that other groups have successfully targeted the eye, and that Sangamo may soon refine delivery to the brain. But he agreed that transporting drugs into the right tissues is a looming question. “I’m convinced the secret to the future use and application of editing is about delivery,” he said.

Correction (May 18): In the fifth paragraph we replaced the word "nick" with "cut" because the zinc finger nucleases make a double-stranded break, not a single-stranded nick. The Scientist regrets any confusion.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

May 20, 2017

Unfortunately, scientists at Sangamo Therapeutics seem to have overlooked the fundamental property of CELL TURNOVER that applies to all human tissues to varying degrees.  Although liver has one of the slower cell turnover rates, the rate is still substantial on the scale of the human lifespan.  The estimated lifetime for a human hepatocytes ranges for 151 to 453 days (MacDonald, 1961).  Hepatocyte division, per se, is not the problem.  The problem is cell turnover, which means that mature hepatocytes that have stopped dividing are lost from the liver either by apoptosis or by physical loss into central veins.  So, in the best case scenario, if Sangamo's treatments only modify hepatocytes, they will not acheive "a lifelong solution."  Treatments are predicted to appear stable for about a year or so before failing.

The key to achieving lifelong gene therapy or gene-editing cures is targeting liver tissue stem cells.  Tissue stem cells can also be lost to apoptotic events with increasing age.  However, the rate of these events is predicted to be much lower than the rate of mature cell turnover.  If a sufficient number of liver stem cells could be modified, then effective therapies on the scale of the human lifespan might be achieved routinely.

James Sherley @ Asymmetrex

jsherley@asymmetrex.com

asymmetrex.com

MacDonald, R. A. (1961). Lifespan of liver cells. Arch. Intern. Med., 107, 335-343.

See also:

http://asymmetrex.com/asymmetrex-says-to-intellia-therapeutics-dont-forget-the-stem-cells-call-us/

http://asymmetrex.com/asymmetrex-continues-to-court-gene-editing-companies/

http://asymmetrex.com/asymmetrex-renews-efforts-to-help-gene-editing-companies/

http://asymmetrex.com/why-gene-therapy-depends-on-counting-stem-cells/

http://asymmetrex.com/time-to-count-stem-cells-solution-for-bluebird-bio/

 

Popular Now

  1. Major German Universities Cancel Elsevier Contracts
  2. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  3. Most of Human Genome Nonfunctional: Study
  4. Identifying Predatory Publishers
AAAS